Navigation Links
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Date:11/8/2011

rket basis in 2012 and 2013. Amylin will work with Lilly on all plans for markets outside the U.S. during the transition period and will guarantee that Lilly does not experience losses on exenatide-related activities during that period, up to a total cap of $60 million.

The Amylin and Lilly alliance resulted in several innovations in the diabetes market. These innovations include the 2005 launch of the first-in-class GLP-1 receptor agonist, BYETTA, a treatment that has been used by 1.8 million patients worldwide, and submission of the first once-weekly GLP-1 receptor agonist, BYDUREON, an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON received marketing authorization in the European Union in June 2011 and is currently under review in the U.S., with a Prescription Drug User Fee Action (PDUFA) date of January 28, 2012. Amylin will continue to evolve the GLP-1 market with the exenatide franchise through the development of a pen device for BYDUREON and the exenatide monthly suspension program.

Amylin to Host Investor Conference Call

Amylin will host a conference call to discuss the transition of the exenatide franchise today at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will lead the call. A slide presentation accompanying the conference call will be available through the "Investors" section of Amylin's corporate website at www.amylin.com.

The call will be webcast live through the "Investors" section of Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately 15 minutes prior to the call to register, download and install any necessary audio software. For those without access to the Inte
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
2. Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership
3. Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal
4. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
5. Lilly Reports Third-Quarter 2011 Results
6. Lilly Declares Fourth-Quarter 2011 Dividend
7. Lilly Announces Changes in Senior Management
8. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
9. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
10. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
11. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  PARI Respiratory Equipment has ... ® .  Kitabis Pak, approved by the FDA on December ... with a PARI LC PLUS ® Nebulizer for patients ... the hard work we put into this unique product offering ... is easy for patients to use, we also wanted to ...
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) ... Future of Pharmaceutical Outsourcing" report to their ... desperate need to develop better drugs with high ... been increasingly utilizing external resources to increase their ... their internal operation. Their outsourcing demands and proportions ...
(Date:6/3/2015)... , June 3, 2015 Mylan N.V. (Nasdaq: ... the Company will present at Goldman Sachs 36 th ... presentation is scheduled to begin at 4 p.m. PT / ... a live webcast of the presentation via the investor relations ... Mylan is a global pharmaceutical company committed to setting ...
Breaking Medicine Technology:Kitabis Pak Wins American Package Design Award 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... (NYSE: SHP ) ("ShangPharma" or the "Company"), a ... today announced that it will release its unaudited financial results ... May 19, 2011. Management will host a conference call to ... 19, 2011 (8:00pm Beijing time on May 19, 2011). ...
... 2011 Mithridion, Inc., a privately-owned clinical stage drug ... disorders, announces that the U.S. Food and Drug Administration ... lead drug candidate, for the treatment of Progressive Supranuclear ... to seven years of market exclusivity upon approval of ...
Cached Medicine Technology:ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011 2FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy 2FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy 3
(Date:6/3/2015)... June 03, 2015 Peter Piot, MD, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... President’s Award for Outstanding Contribution to Global Health that ... to advancing global health. , “DIA is ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Researchers at ... biomarkers for mesothelioma and say the tried-and-true marker mesothelin ... posted an article on the research. Click here ... University’s National Center for Asbestos Related Diseases say, even ... results, it is still preferable to fibulin-3 for identifying ...
(Date:6/3/2015)... 2015 Sitting at a computer for ... the back, neck, shoulders and/or wrists. This can lead ... addition, recent research links sitting for long periods as ... Fortunately, three inventors from Oakville, Ontario, are offering an ... , They have developed a prototype for a patent-pending ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On Sunday, ... the world will gather in their local communities to ... of cities across the U.S. and abroad will hold ... bring attention to the ongoing challenges of cancer survivorship, ... cancer diagnosis can be fruitful, rewarding, and inspiring.,  , ...
Breaking Medicine News(10 mins):Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4
... adipose tissue, or the layer of fat around the heart, ... as coronary artery calcium scoring, according to research by cardiologists ... layer of fat around the heart can be measured by ... information may be used as a ,gate keeper, in that ...
... (March 15, 2010) New research findings published in the ... of Surgeons indicate that some breast cancers continue to ... through mammographic screening. Patients who presented with palpable tumors ... examination had larger tumors and were at a more ...
... Plastic Surgery Arts ... a new reconstructive breast surgery program at Hunterdon Regional Cancer Center. Dr. Nini is a ... , ... -- Plastic Surgery Arts of New Jersey (PSANJ) is proud to announce that Dr. Kevin ...
... March 15 The Dallas-Fort Worth Business Group on Health (DFWBGH), a non-profit coalition of large private and public employers throughout North Texas focused on enhancing the ... ... ... ...
... odds of not drinking, researchers say , MONDAY, March ... Zoloft (sertraline) and the alcoholism drug naltrexone improves the ... dependence will be able to stop drinking, U.S. researchers ... that 54 percent of those who received the combined ...
... ... wrestles with their own Trillion Dollar Question: How do we increase employee productivity ... Inc. the maker of Sweat365.com, unveils “The Healthy Corp” a breakthrough product that ... ...
Cached Medicine News:Health News:Imaging fat layer around heart can help predict disease 2Health News:Palpable breast cancers are more common in women not undergoing annual mammography 2Health News:Palpable breast cancers are more common in women not undergoing annual mammography 3Health News:Dr. Kevin Nini to Lead Reconstructive Breast Surgery Program at Hunterdon Regional Cancer Center 2Health News:Dr. Kevin Nini to Lead Reconstructive Breast Surgery Program at Hunterdon Regional Cancer Center 3Health News:Dallas-Fort Worth Business Group on Health Elects New Board Members 2Health News:Dallas-Fort Worth Business Group on Health Elects New Board Members 3Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 2Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 3
Plastic Economical Single use. Non-Sterile....
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... Ruschelit® PVC. 2 eyes, oral. Marked ... age. X-ray opaque line. Graduated. Single ... Designed to reduce kinking of the ... Thermosensitive Ruschelit® PVC adapts to the ...
Medicine Products: